NEW YORK, March 12 - CuraGen and Alexion Pharmaceuticals on Tuesday said they have signed a deal to discover and validate cancer-related biologic and small-molecule drug targets.

Terms of the multi-year agreement, which may grow in the future to include other diseases, call for CuraGen to apply its functional genomic technologies to help Alexion identify drug targets from data the biotech company will provide.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.